Why is PCOS treated as a metabolic condition?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
PCOS is treated as a metabolic condition because insulin resistance sits underneath the hormonal picture in a large share of cases. High insulin drives the ovary to make more testosterone and lowers sex hormone binding globulin, which raises free testosterone further. The 2023 international guideline states the risk of type 2 diabetes is increased regardless of age and body weight.
PCOS is a reproductive diagnosis with a metabolic engine. Insulin resistance is common in PCOS and it does two things at once: it pushes the ovarian theca cells to produce more androgen, and it suppresses sex hormone binding globulin made by the liver, so a larger fraction of the testosterone already present is free and active. That is why the same condition produces both irregular cycles and acne, hair growth and weight that is hard to shift.
How insulin raises testosterone
In PCOS, insulin acts as a co-gonadotrophin. Alongside luteinising hormone, it stimulates androgen output from the ovary. At the same time, insulin lowers hepatic production of sex hormone binding globulin, the carrier protein that keeps most circulating testosterone inactive. Lower carrier protein means higher free testosterone at the same total level. This is the mechanism behind the observation that lowering insulin, by whatever route, tends to lower androgen symptoms over months rather than days.
What the guideline says about diabetes risk
The 2023 International Evidence-based Guideline states that women with PCOS have an increased risk of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes "regardless of age and BMI". It recommends the 75 g oral glucose tolerance test as the most accurate test of glycaemic status in PCOS, again regardless of BMI, and reassessment every one to three years depending on other risk factors. Fasting glucose and HbA1c alone miss a meaningful number of these cases.
What this changes about treatment
Framing PCOS as metabolic changes what gets measured and what gets treated. It means a lipid profile at diagnosis regardless of age and BMI, annual blood pressure, and screening for obstructive sleep apnoea, which the guideline notes is more common in PCOS independent of body weight. It also explains why metformin is positioned for metabolic features rather than for periods, and why exercise plus a diet the person can actually sustain sits at the base of every treatment plan.
| Test | Why it is used in PCOS | Guideline position |
|---|---|---|
| 75 g oral glucose tolerance test | Detects post-load glucose rises that fasting tests miss | Most accurate test, regardless of BMI |
| HbA1c or fasting glucose | Convenient, no fasting load needed | Acceptable but less sensitive in PCOS |
| Fasting insulin or HOMA-IR | Estimates insulin resistance | Research tool, not a diagnostic criterion |
| Lipid profile | Cardiovascular risk assessment | At diagnosis in all women with PCOS |
If you have PCOS and have never had an oral glucose tolerance test, that is the single test to ask for. Bring the result back with your lipids and blood pressure, and set a recheck interval of one to three years rather than leaving it open.
The clinical detail
2023 guideline recommendations: glycaemic status assessed by 75 g OGTT as the most accurate test regardless of BMI (1.9.9), reassessed every one to three years based on individual risk factors (1.9.3). Lipid profile including total cholesterol, LDL-C, HDL-C and triglycerides at diagnosis in all women with PCOS regardless of age and BMI (1.8.3). Blood pressure annually and when planning pregnancy or fertility treatment (1.8.4).
NIDDK prediabetes cut-offs apply: HbA1c 5.7 to 6.4 per cent, fasting plasma glucose 100 to 125 mg/dL, two hour OGTT glucose 140 to 199 mg/dL. HOMA-IR is calculated from fasting insulin and glucose but has no validated diagnostic threshold in PCOS and no assay standardisation across labs, so it is used to track a trend rather than to label a person.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- International Evidence-based Guideline for the Assessment and Management of PCOS, 2023 summary. Monash University Centre for Health Research and Implementation
- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism. PMID 37580314
- Insulin Resistance and Prediabetes. NIDDK, National Institutes of Health
- Polycystic ovary syndrome: an update on diagnosis and management (2026). Cleveland Clinic Journal of Medicine
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.